CareLit · DOI-Nachweis · Nuklearmedizin - NuclearMedicine
First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study
DOI 10.1055/a-2652-3273
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJonathan Miksch, Elham Yousefzadeh-Nowshahr, Deni Hardiansyah, Gerhard Glatting, Christoph Solbach, Christian Bolenz, Friedemann Zengerling, Thomas Wiegel, Meinrad Beer, Vikas Prasad, Hans-Jürgen Wester, Ambros J. Beer, Wolfgang Thaiss
ZeitschriftNuklearmedizin - NuclearMedicine
Ausgabe05/2025
Jahrgang / SeitenJg. 64 · S. 285-293
Kernaussage aus der Literatur
Abstract-Vorschau
Abstract Aim Silicon-based ligands are of interest in increasingly used Prostate-specific membrane antigen (PSMA) tracers for prostate cancer (PCa) staging due to their simple and scalable production. Here, we present first data on dosimetry and biodistribution of the novel PSMA-specific tracer [¹⁸F]siPSMA-14. Methods Seven PCa patients referred for PSMA-PET/CT imaging were imaged at 60 and 120 min p.i. (T1 and T3),…
Zitieren
Zitierempfehlung
Jonathan Miksch, Elham Yousefzadeh-Nowshahr, Deni Hardiansyah, Gerhard Glatting, Christoph Solbach, Christian Bolenz, Friedemann Zengerling, Thomas Wiegel, Meinrad Beer, Vikas Prasad, Hans-Jürgen Wester, Ambros J. Beer, Wolfgang Thaiss (2025) First clinical application of silicon-based [¹⁸F]siPSMA-14 in prostate cancer patients: A proof-of-concept study. Nuklearmedizin - NuclearMedicine, 64 (05), 285-293. https://doi.org/10.1055/a-2652-3273
Mit CareLit weiterarbeiten